Thu, Aug 21, 2014, 9:12 AM EDT - U.S. Markets open in 18 mins.

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • wilderguide wilderguide Dec 7, 2012 6:36 PM Flag

    Wall Street doesn't like the word "unprecedented"...

    $$$$

    Thanks for the positive reinforcement, urabt2.
    If Ernie's intuitive assertion wrt DTC compendia listing is correct ( I absolutely believe it is...) the shorts have but numbered days to exercise control of EXEL. The more they play, the more I buy. The lower they drive the valuation, the greater the chance of an interventional buy-out. In the midst of a diminished share price, the clinical data just gets better and better...which means that a buy-out valuation has nowhere to go but upward. The clinical positivity is outstanding.

    Cometriq is soon to develop a profound rate of clinical adoption that will rival that of Gleevec, and - as shareholders - we have some off-the-radar NCCN dates of colossal stock valuation importance to recognize. I am still in research to deliver full-length on this topic, and will return to it when my findings are mature enough to share w/ all. The holiday season is simply not the best-of-times for information gathering.
    Cash post-approval bonuses have just today been announced at Exelixis.
    The shareholder bonus party begins in 2013.
    Have a good holiday.
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
EXEL
4.11Aug 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.